Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

A Multicenter, Randomized, Parallel Group, Comparative, Active-Controlled, Safety-Assessor Blinded, Phase IIIa, Trial, in Adult Subjects Comparing Recovery From 1.2 mg.Kg-1 Rocuronium Followed by 16 mg.Kg-1 Org 25969 at 3 Minutes With Recovery From 1.0 mg.Kg-1 Succinylcholine

The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 1.2 mg/kg rocuronium after reversal at 3 minutes by 16.0 mg/kg of sugammadex compared with recovery after a neuromuscular block induced by 1.0 mg/kg succinylcholine.

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) Class 1 or 2 physical status;
• 18 to 65 years of age (inclusive);
• Scheduled for elective surgical procedure under general anesthesia requiring a short duration of neuromuscular block with the use of rocuronium or succinylcholine and requiring endotracheal intubation;
• Scheduled for surgery in supine position;
• Body mass index (BMI) < 30;
• Given written informed consent.

Exclusion Criteria:

• Has ischemic heart disease or history of myocardial infarction within the last year;
• May experience difficult intubation due to anatomical malformations;
• Known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction;
• Known or suspected family history of malignant hyperthermia;
• Known or suspected allergy to narcotics, muscle relaxants, midazolam, anesthetics or other medications used during surgery;
• Is receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and Mg2+;
• Individuals in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;
• Females who are pregnant or breast-feeding;
• Females of childbearing potential who are not using an acceptable method of birth control [condom or diaphragm with spermicide, vasectomized partner (> 6 months), IUD, abstinence];
• Has already participated in a sugammadex trial including Protocol 19.4.303.